<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>PHHO2013FR001454</report-id><gender>female</gender><reactions><reaction>Right facial paralysis</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>AMN107</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LANZOR</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SERETIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>XYZALL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CITALOPRAM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FORLAX</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication><indication>Gastrooesophageal reflux disease</indication><indication>Bronchitis chronic</indication><indication>Bronchitis</indication><indication>Sleep disorder</indication><indication>Constipation</indication></indications><outcomes/><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149689_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152630</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHO2013FR001454</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2013FR001454</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CAMN107A2303</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypotension</patientepisodename>
				<patientmedicalcomment>In 1967</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bronchitis</patientepisodename>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20120110</patientmedicalenddate>
				<patientmedicalcomment>In 1974</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Atrioventricular block first degree</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20080626</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bundle branch block left</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20080626</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20101007</patientmedicalenddate>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Electrocardiogram T wave inversion</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20080626</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20101222</patientmedicalenddate>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Poisoning</patientepisodename>
				<patientmedicalcomment>In 1967</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Constipation</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Osteoarthritis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Sleep disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bronchitis chronic</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Gastrooesophageal reflux disease</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Right facial paralysis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Facial paralysis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>VIIth nerve paralysis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121118</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20130107</reactionenddate>
				<reactionduration>51</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>781</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Computerised tomogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Haematology test</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Investigation</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121217</testdate>
				<testname>Nuclear magnetic resonance imaging</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>468600</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>300 mg, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-09-30</drugstartdate>
				<drugstartperiod>781</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-12-19</drugenddate>
				<drugtreatmentduration>812</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>VIIth nerve paralysis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>VIIth nerve paralysis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>468600</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>300 mg, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2013-01-17</drugstartdate>
				<drugstartperiod>781</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>VIIth nerve paralysis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>VIIth nerve paralysis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LANZOR</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>15 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Gastrooesophageal reflux disease</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-05-03</drugstartdate>
				<drugstartperiod>202</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>LANSOPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>SERETIDE</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugdosagetext>250 BID</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bronchitis chronic</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-02-09</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>XYZALL</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>5 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bronchitis</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>LEVOCETIRIZINE DIHYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CITALOPRAM</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>200</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>200 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Sleep disorder</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2007-09-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CITALOPRAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>FORLAX</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="002">grams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>10 g, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Constipation</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-11-04</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>MACROGOL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2013FR001454, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>report received on 22 Jan 2013, from clinical study CAMN107A2303. This 63-year old female subject (centre number 150, subject number 13) was enrolled in a phase III multi center, open label, randomized study of <Semaphore x="699336" class="Medicine" value="imatinib" score="0.49" ID="252378">imatinib </Semaphore>versus <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib </Semaphore>in <Semaphore x="2102861" class="Occupation" value="Legal Occupations" score="1.00" ID="C97637">adult </Semaphore>patients with newly <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore><Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174"><Semaphore x="2859866" class="MedDRA LLT" value="Chromosome analysis abnormal" score="1.00" ID="10008817">Philadelphia chromosome positive </Semaphore>(Ph+) <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">chronic <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175"><Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myelogenous leukemia </Semaphore>
                      </Semaphore></Semaphore></Semaphore>
    <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">
     <Semaphore x="1781597" class="Disease or Finding" value="Chronic Pulmonary Heart Disease" score="1.00" ID="C34478">
      <Semaphore x="1781581" class="Disease or Finding" value="Chronic Prostatitis" score="1.00" ID="C26930">
       <Semaphore x="1781563" class="Disease or Finding" value="Chronic Polyneuropathy" score="1.00" ID="C36071">
        <Semaphore x="1781545" class="Disease or Finding" value="Chronic Phase of Disease" score="1.00" ID="C36154">
         <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
          <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">
           <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
            <Semaphore x="2860414" class="MedDRA LLT" value="Chronic leukaemia" score="1.00" ID="10008943">
             <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
              <Semaphore x="2861453" class="MedDRA LLT" value="Chronic myeloid leukaemia" score="1.00" ID="10009013">
               <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">
                <Semaphore x="1781597" class="Disease or Finding" value="Chronic Pulmonary Heart Disease" score="1.00" ID="C34478">
                 <Semaphore x="1781581" class="Disease or Finding" value="Chronic Prostatitis" score="1.00" ID="C26930">
                  <Semaphore x="1781563" class="Disease or Finding" value="Chronic Polyneuropathy" score="1.00" ID="C36071">
                   <Semaphore x="1781545" class="Disease or Finding" value="Chronic Phase of Disease" score="1.00" ID="C36154">
                    <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
                     <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">in <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175"><Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic </Semaphore>
                       </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
              <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">
               <Semaphore x="1781597" class="Disease or Finding" value="Chronic Pulmonary Heart Disease" score="1.00" ID="C34478">
                <Semaphore x="1781581" class="Disease or Finding" value="Chronic Prostatitis" score="1.00" ID="C26930">
                 <Semaphore x="1781563" class="Disease or Finding" value="Chronic Polyneuropathy" score="1.00" ID="C36071">
                  <Semaphore x="1781545" class="Disease or Finding" value="Chronic Phase of Disease" score="1.00" ID="C36154">
                   <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
                    <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
                     <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
                      </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
            <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
             <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">
              <Semaphore x="1781597" class="Disease or Finding" value="Chronic Pulmonary Heart Disease" score="1.00" ID="C34478">
               <Semaphore x="1781581" class="Disease or Finding" value="Chronic Prostatitis" score="1.00" ID="C26930">
                <Semaphore x="1781563" class="Disease or Finding" value="Chronic Polyneuropathy" score="1.00" ID="C36071">
                 <Semaphore x="1781545" class="Disease or Finding" value="Chronic Phase of Disease" score="1.00" ID="C36154">
                  <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
                   <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
                    <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">phase </Semaphore></Semaphore>
                   </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
             <Semaphore x="1781597" class="Disease or Finding" value="Chronic Pulmonary Heart Disease" score="1.00" ID="C34478">
              <Semaphore x="1781581" class="Disease or Finding" value="Chronic Prostatitis" score="1.00" ID="C26930">
               <Semaphore x="1781563" class="Disease or Finding" value="Chronic Polyneuropathy" score="1.00" ID="C36071">
                <Semaphore x="1781545" class="Disease or Finding" value="Chronic Phase of Disease" score="1.00" ID="C36154">
                 <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
                  </Semaphore></Semaphore>
                </Semaphore>
               </Semaphore>
              </Semaphore>
             </Semaphore>
            </Semaphore></Semaphore>
          <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">
           </Semaphore></Semaphore></Semaphore>
        <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
         </Semaphore></Semaphore>
       <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
        </Semaphore></Semaphore>
      <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
       </Semaphore></Semaphore>
     <Semaphore x="1781524" class="Disease or Finding" value="Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3175">
      <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">(<Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">CML </Semaphore></Semaphore></Semaphore></Semaphore>
    CP).The subject’s medical history included <Semaphore x="2041846" class="Disease or Finding" value="Hypotension" score="1.00" ID="C3128">hypotension</Semaphore>, <Semaphore x="2765453" class="MedDRA LLT" value="Asthma" score="1.00" ID="10003553">asthmatic <Semaphore x="1650011" class="Disease or Finding" value="Bronchitis" score="1.00" ID="C2911">bronchitis</Semaphore></Semaphore>, <Semaphore x="1558734" class="Disease or Finding" value="AV Block First Degree by ECG Finding" score="1.00" ID="C111088">first degree AV <Semaphore x="1606536" class="Procedure" value="Block Dissection of Inguinal Lymph Nodes" score="1.00" ID="C51620">block </Semaphore></Semaphore><Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>1, left anterior hemi <Semaphore x="1606536" class="Procedure" value="Block Dissection of Inguinal Lymph Nodes" score="1.00" ID="C51620">block </Semaphore><Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>2, <Semaphore x="2924730" class="MedDRA LLT" value="Electrocardiogram T wave inversion" score="1.00" ID="10014395"><Semaphore x="1776464" class="Procedure" value="Chromosomal Translocation Analysis" score="1.00" ID="C63326">T </Semaphore>waves inverted</Semaphore>, tabagic <Semaphore x="2070245" class="Disease or Finding" value="Intoxication" score="1.00" ID="C28283">intoxication</Semaphore>, <Semaphore x="1810939" class="Procedure" value="Constipation at its Worst" score="1.00" ID="C105544">constipation</Semaphore>, <Semaphore x="3160872" class="MedDRA LLT" value="Osteoarthritis" score="1.00" ID="10031161">arthrosis</Semaphore>, <Semaphore x="2529551" class="Disease or Finding" value="Sleep Disorder" score="1.00" ID="C3376">sleep disorder</Semaphore>, <Semaphore x="1965163" class="Disease or Finding" value="Gastroesophageal Reflux Disease" score="1.00" ID="C26781">GERD </Semaphore>and obstructive chronic <Semaphore x="2829475" class="MedDRA LLT" value="Bronchial disorder" score="1.00" ID="10064913">bronchopathy</Semaphore>. Concomitant medications included Lanzor, Seretide, Xyzall, <Semaphore x="363739" class="Medicine" value="Citalopram" score="0.49" ID="251596">citalopram</Semaphore>, “tobalgic” and Forlax. The subject started the study medication on 30 Sep 2010 at a dose of 600 mg per day. On 18 Nov 2012, the subject experienced right <Semaphore x="2920343" class="MedDRA LLT" value="Ear pain" score="1.00" ID="10014020">otalgia </Semaphore>without <Semaphore x="1932946" class="Disease or Finding" value="Fever" score="1.00" ID="C3038">fever</Semaphore>. On 20 Nov 2012, the subject had right <Semaphore x="1918283" class="AnatomicStructure" value="Face" score="1.00" ID="C13071">facial </Semaphore><Semaphore x="2373536" class="Disease or Finding" value="Paralysis" score="1.00" ID="C3310">paralysis </Semaphore>with <Semaphore x="2008813" class="Disease or Finding" value="Headache" score="1.00" ID="C34661">headache</Semaphore>. On 22 Nov 2012, the subject’s <Semaphore x="1746366" class="AnatomicStructure" value="Cerebral Hemisphere" score="1.00" ID="C12351">cerebral </Semaphore><Semaphore x="2871950" class="MedDRA LLT" value="Computerised tomogram" score="1.00" ID="10010234">CT <Semaphore x="2444079" class="Procedure" value="Radionuclide Imaging" score="1.00" ID="C62667">scan </Semaphore></Semaphore>and hematology <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were normal. On the same day, she was treated with Zelitrex and <Semaphore x="1081881" class="Medicine" value="predniSONE" score="0.49" ID="291353">prednisone</Semaphore>. On 10 Dec 2012, the subject had second occurrence of <Semaphore x="2373536" class="Disease or Finding" value="Paralysis" score="1.00" ID="C3310">paralysis </Semaphore>with right <Semaphore x="2920343" class="MedDRA LLT" value="Ear pain" score="1.00" ID="10014020">otalgia</Semaphore>. The clinical examination <Semaphore x="2592399" class="Race" value="Sugpiaq" score="1.00" ID="C44488">suggested </Semaphore>a <Semaphore x="2023303" class="Disease or Finding" value="Herpes Zoster Dermatitis of Eyelid" score="1.00" ID="C34696">zoster </Semaphore><Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection </Semaphore>in the subject. She was treated with Zelitrex, Monoalgic and <Semaphore x="804590" class="Medicine" value="Lyrica" score="0.49" ID="275868">Lyrica</Semaphore>. On 17 Dec 2012, the subject’s <Semaphore x="3146801" class="MedDRA LLT" value="Nuclear magnetic resonance imaging normal" score="1.00" ID="10029823"><Semaphore x="2149241" class="Procedure" value="Magnetic Resonance Imaging" score="1.00" ID="C16809">MRI </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">result </Semaphore>was normal</Semaphore>. On 19 Dec 2012, study medication was temporarily discontinued due the event. On 07 Jan 2013, <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was complete resolved. On 17 Jan 2013, <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">treatment with the study medication </Semaphore>was restarted. The event was considered serious (medically significant) by the investigator.The investigator considered the event (<Semaphore x="1918283" class="AnatomicStructure" value="Face" score="1.00" ID="C13071">facial </Semaphore><Semaphore x="2373536" class="Disease or Finding" value="Paralysis" score="1.00" ID="C3310">paralysis</Semaphore>) was possibly related to <Semaphore x="2690730" class="Disease or Finding" value="Viral Infection" score="1.00" ID="C3439">viral infection</Semaphore>.The investigator reported that the event was suspected to the study medication.</narrativeincludeclinical>
				<sendercomment>Zoster infection could provide an alternative causality.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>